Eli Lilly and Co. (LLY) announced Friday the successful completion of its acquisition of Verve Therapeutics, Inc. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Lilly said the acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment.
On June 17, Lilly agreed to acquire Verve for up to $13.50 per share or up to around $1.3 billion, including around $1.0 billion in cash.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.